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Purpose: to determine the 12 months success rate with a balloon expandable, flexible stainless steel stent in iliac artery
obstructions.
Materials and Methods: one-hundred and twenty-six consecutive patients with iliac obstructive disease and who
demonstrated an unsatisfactory angioplasty result with a post-dilatation gradient of at least 10 mmHg, or a primary
occluded lesion were included in the study. Follow-up was by Doppler sonography, ankle pressures with and without
exercise and clinical parameters.
Results: after stent placement, the mean percentage diameter stenosis decreased from 79 to 4%, with a mean intra-arterial
pressure gradient of 3 mmHg. Primary stent patency was 94% at 6 months and 89% at 12 months. Primary clinical result
at 6 months was 88% and at 12 months 81%. Primary assisted clinical result (after re-pta) at 6 and 12 months was 89 and
86%, respectively. The Ankle Brachial Index (ABI) after exercise at 1 month follow-up was reduced from 0.88 to 0.75, with
minor deterioration at 6 months to 0.72, and at 12 months to 0.68. The 1, 6, and 12 months follow-up Piek Systolic Velocity
(PSV) ratios across the stented lesions remained stable at a mean of 1.4, 1.6, and 1.6, respectively. However, respectively 44,
39 and 34% of the patients still experienced symptoms of claudication.
Conclusions: the results presented here support the suggestion stenting to be an effective device in the treatment of iliac
artery obstructive disease. This study also, confirms other study results concerning haemodynamic patency after iliac
stenting on the indication of a 10 mmHg pressure gradient after pta and the discrepancy between good haemodynamic
patency and clinical result.
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Introduction
The application of stents for the treatment of periph-
eral vascular disease has increased since its inception
just more than a decade ago. Publications on stent
implantation in iliac arteries have reported improved
immediate angiographic and haemodynamic out-
comes after suboptimal balloon angioplasty in diffi-
cult cases and complications arising during simple
balloon angioplasty.1,2
Data published on different types of metallic stents
applied in iliac arteries have not demonstrated
significant differences in terms of technical success
and follow-up outcomes.3±5 In the current prospective
non-randomised study, we report on the use of a
flexible, stainless steel balloon expandable stent in
the treatment of iliac artery obstructive disease.
Patients received a stent following suboptimal balloon
angioplasty as determined by intra-arterial pressure
measurements, or in cases of restenosis or lesion
occlusion. This paper describes the outcomes to 12
months follow-up.
Materials and Methods
Patients
From February to December 1997, 10 centres in five
European countries recruited 126 consecutive patients
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with iliac obstructive disease (symptomatic claudica-
tion or rest pain, scheduled to undergo percutaneous
transluminal angioplasty of a stenotic or occluded
lesion in a common and/or external iliac artery) in a
multicentre, prospective, and non-randomised study.
The 100 men and 26 women were 61 (range 39±78)
years old. All participating physicians were experi-
enced in peripheral vascular interventional techni-
ques. The local institutional review boards approved
the study protocol. All patients provided written
informed consent prior to the undergoing the inter-
ventional procedure.
Study patients were enrolled according to the follow-
ing inclusion criteria: patients with life-style limiting
claudication or rest pain; lesions in the common (CIA)
or external (EIA) iliac artery with an angiographically
documented unsatisfactory angioplasty result which
potentially included de novo lesions with a mean pres-
sure gradient (MPG) after predilatation of at least
10 mmHg following vasodilator challenge or restenotic
lesions with a MPG of at least 10 mmHg following
vasodilator challenge or occluded lesions (primary
stent placement); and stented segment (lesions singular
or multiple) 510 mm in diameter and 510 cm in
length. Patient exclusion criteria included: tissue loss
(category 5 or 6 of the SCVIR classification); less than 1
year previously implanted stents in the target vessel;
lesions with large amount of adjacent thrombus; no
patent femoral artery on the treated side. A segment
comprising multiple stenoses was considered as a
single lesion.
Stent design
The stent applied in this study was a peripheral stain-
less steel stent, the Cordis PerflexTM stent (Cordis, a
Johnson & Johnson Company, Roden, The Nether-
lands). The stent is made from a single diameter stain-
less steel wire, formed into a singular plane sinusoidal
wave pattern, wrapped in a tubular helical fashion.
The tube is maintained by a series of welded joints.
The number of consecutive weld joints varies with the
length of the stent and forms the backbone of the stent.
These spines are opposed to one another radially and
equidistantly around the circumference of the stent.
The dimensions of the stents available for the study
were: 7 mm and 8 mm diameter in the lengths 35 mm,
55 mm and 75 mm; 9 mm diameter in lengths of 35 mm
and 55 mm; and 10 mm diameter by 35 mm length.
The recommended introducer sheath size for the 7 mm
and 8 mm is 8 F and for the 9 mm and 10 mm stents,
8.5 F. The stent is pre-mounted on a balloon catheter.
This stent was never commercially available.
Study objectives
The primary objective of this study was to determine
the patency after stenting and the primary clinical
result in patients with symptomatic claudication and
rest pain, scheduled to undergo percutaneous trans-
luminal angioplasty of a stenotic, restenotic or
occluded lesion in a CIA or EIA. The primary endpoint
was primary clinical result defined as the absence of a
reintervention that may preserve or extend patency of
the treated lesion and absence of a more than 0.15
deterioration of the maximum early ABI and a
downward change in the SCVIR classification.
Secondary objectives were the acute performance of
stent and delivery system; the evaluation of the haemo-
dynamic status of the stent after 1, 6, and 12 months
post-implantation; and the evaluation of the short and
longer term safety of the device. The secondary end-
points were: stenting procedural success defined as
angiographic success (reduction by at least 20% and
residual percentage stenosis of the implanted lesion
less than 30%), with less than 10 mmHg mean residual
pressure gradient following vasodilator challenge
(100 Tgm Nitrogycerine intra-arterial); haemodynamic
failure defined as a peak systolic velocity (PSV) ratio
of 42.5 or the absence of a Doppler signal of the
stented lesion; assisted primary patency on a failing
but patent stent; and secondary patency defined as
rescue of a failed stent.
Treatment protocol
Prior to undergoing the interventional procedure, vas-
cular and nonvascular clinical history (including risk
factors, medical and surgical cardiovascular back-
ground, and current symptoms) and demographic
data were collected and pre-angiographic haemody-
namic examinations (ABI at rest and following exer-
tion, measurement of PSV proximal, above and distal
from the lesion by duplex echography) were per-
formed. The mean pressure gradient measurements
were obtained according to local practice.
At 1, 6, and 12 months post-implantation, clinical
evaluation of all patients was performed and included
clinical examination, ABI measurement during rest
and after exercise, and Duplex scanning of the
treated limb.
Statistical analysis
Statistical analysis was performed by using the
two-sample t-test with a significance level of p 0.05.
512 J. A. Reekers et al.
Eur J Vasc Endovasc Surg Vol 24, December 2002
Results
Procedure outcomes
In 126 patients, 143 limbs with 153 lesions were treated
with 182 stents. Of the 126 patients, baseline character-
istics are summarised in Tables 1 and 2, respectively.
Of the lesions, 91% were de novo while 7% were rest-
enotic (2% not known). No lesions contained thrombus
(study exclusion criterion). All stents were successfully
implanted. Procedural success (420% lesion reduc-
tion and residual stenosis 530% with 510 mmHg
pressure gradient) was 94%. Of the 26 lesions treated
by primary stent placement, 16 were total occlusions;
primary stenting was performed in the other 10 lesions
for dissections resulting from recent coronary and sur-
gical procedures (n 2), restenosis (n 2), high
(480%) grade stenosis with a high pressure gradient
(n 5), and low grade (35%) stenosis with high pres-
sure gradient (n 1). The latter six were protocol
violations. Intraluminal pressure measurements of
pre-dilated lesions demonstrated a mean pressure
gradient of 410 mmHg (a study inclusion criterion).
After stent placement, the mean percentage stenosis
was 47% (range: 0±40%) and there was a reduction in
the mean intra-arterial pressure gradient to 3 mmHg
(range: 0±22 mmHg) (Table 3). Seven lesions demon-
strated a 410 mmHg after stenting. In our series, 85
(68%) patients received one stent and 41 (32%) pati-
ents 41 stents (max. 5). Procedure complications
occurred 3%, 2 peripheral embolisations and 2 major
haematomas.
Follow-up outcomes
Primary patency at 1, 6, and 12 months, as determined
by PSV ratios, was 96, 94, and 89%, respectively. The
clinical result on an intention-to-treat basis at 6-months
was 88% and at 12 months 81%. Re-intervention was
required in one patient (0.8%) at 3.5 months and in five
patients (4%) between 6 and 12 months, resulting in an
assisted clinical result of 89 and 86%, respectively.
Clinical data assessed during the follow-up period
to 12 months revealed 71% of limbs to have remained
in the same clinical grade. There was further improve-
ment in 11% (10% by 1 grade and 1% by 2 grades)
while for 18% there was a decrease in category (9%
decrease of 1 and 9% of 2 grades). Table 4 details the
percentage of patients in each clinical grade during
the follow-up period.
Throughout the follow-up period the haemodynamic
status at rest was shown to have remained at the same
level as was measured immediately post-stenting
(Table 5). The mean ABI after exercise progressively
Table 1. Patient clinical characteristics.
History n (%)
Coronary artery disease 38 (30)
Cerebral vascular disease 17 (13)
Family history atherosclerosis 49 (39)
Tobacco use 74 (59)
Hypercholester. 46.5 mmol/l 56 (44)
Diabetes mellitus 17 (13)
Table 2. Baseline lesion characteristics.
Total number of lesions n 153
Arterial segment
Aorta bifurcation 5 (3%)
Common iliac artery 75 (49%)
External iliac artery 47 (31%)
Junction common-external iliac artery 26 (17%)
Angiographic lesions
Anatomy
Straight 122 (80%)
Tortuous 28 (18%)
Unknown 3 (2%)
Calcified 108 (67%)
Eccentric 79 (52%)
Length 33 (4±99) mm
Vessel diameter
Proximal to lesion 7.9 1.2 mm
Distal to lesion 7.5 1.3 mm
450% diameter reduction 90%
Total occlusion 10%
Signifies mean SD.
Table 3. Comparison lesion characteristics pre- and post-stenting
procedure.
Characteristic Pre-procedure Post-procedure
Mean % stenosis 79 (35±100)% 4 (0±40)%
Pressure gradient (mmHg) 410 3 (0±22)
Patients with 410 mmHg
gradient after vasodilator
± 7%
Table 4. Comparison of clinical characteristics during the
follow-up period.
Clinical
grade limb
Pre-procedure
(%)
1-month
fu (%)
6-months
fu (%)
12-months
fu (%)
Category 0 3 62 68 65
Category 1 14 23 21 19
Category 2 77 14 10 14
Category 3 6 0 1 2
Category 4 1 1 0 0
No. of
limbs
assessed
143 137 129 118
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deteriorated from mean 0.88 post-procedure to mean
0.75 at 1 month (n.s.d); 0.72 at 6 months (p5 0.05); and
to 0.68 at 12 months (p5 0.05). However, the follow-up
levels remained significantly elevated (p5 0.001) when
compared to the pre-stenting situation (mean 0.44). At
12 months the median walking distance (197 m; range
34±998 m) remained significantly greater when com-
pared to pre-procedure (74 m; range 0±285 m)
(p5 0.005). During the follow-up period the lesion
PSV ratios remained reduced at a mean of 1.4 (range:
1.0±3.5) at 1 month, 1.6 (range: 1.0±4.6) at 6 months, and
1.6 (range: 1±7.2) at 12 months as compared to the mean
pre-stenting ratio of 3.6 (range: 1.0±13.7). PSV ratios
were not assessed immediately post-procedure.
There were 10 (8%) reports of procedure- or stent-
related serious adverse events (SAE), assessed accord-
ing to the protocol, during the study period to
12-months follow-up. These are listed in Table 6.
One patient died just prior to 1-month follow-up
(not study related) during planned bypass surgery
of the contralateral limb. We experienced a lost to
follow-up, despite all efforts, at 1, 6, and 12 months
of respectively 4±12 and 21 patients (25 limbs).
Discussion
Iliac artery PTA has proven its worth, offering high
technical success and low complications rates, with
acceptable long-term patency in most patients.6±8
However, residual stenosis and restenosis can com-
promise PTA success. These can ultimately influence
the long-term outcome for the patient. More than 10
years have elapsed since the first report of the use of
metallic vascular prostheses as an adjunct to PTA.3,4
Since then there has been increasing use of stents in
the treatment of iliac artery disease. Both strategies of
secondary stenting after failed PTA and primary
stenting are currently practised. The only published
randomised study comparing primary angioplasty
followed by selective stent placement and primary
stent placement in patients with iliac artery obstruct-
ive disease (DIST: Dutch Iliac Stent Trial) in both the
short and long term, indicated that selective stent
placement should probably be considered as the
treatment of choice.9
In the current study stent placement was performed
in those patients presenting with intermittent claudi-
cation in whom an insufficient angioplasty result (a
mean pressure gradient of more than 10 mmHg across
the angioplastied lesion) was obtained or in whom
lesions were restenotic or occluded. Although a non-
randomised study, the patient inclusion criteria in this
study are the same as those of the angioplasty fol-
lowed by selective stent group of the DIST study,9 as
are definitions of study endpoints, thereby allowing
direct comparison of various study outcomes. The
technical and procedure success rates (100 and 94%,
respectively) and stent procedure complication rates
(8% procedural, of which 3.2% major) are comparable
to those in the DIST study, in which the Palmaz stent
(Cordis, a J & J Company, Warren. NY, U.S.A.) was
applied, and to other published studies.2±5 Further-
more, the 12-month outcomes of the DIST study and
the current study are also comparable with respect to
primary clinical result (80 and 81%, respectively) and
haemodynamic Duplex stent patency (87%, with 4%
Table 5. Follow-up ABI at rest and following exercise, and haemodynamic status of the stented
lesion.
Pre-procedure Post-procedure 1 month fu 6 months fu 12 months fu
ABI Rest
Median 0.67 0.92 0.96 0.94 0.94
Min. 0 0.30 0.21 0 0.07
Max. 1.19 2.25 1.50 1.40 2.0
ABI
Exercise
Median 0.41 0.87 0.83 0.72y 0.68y
Min. 0 0.30 0.05 0.10 0
Max. 0.95 1.25 1.31 2.58 1.38
Mean PSV
ratio
3.6
(1.0±13.7)
Not done 1.4
(1.0±3.5)
1.6
(1.0±4.6)
1.6
(1±7.2)
 p5 0.005 compared with preoperative values.
{ p5 0.05 compared with previous measurements.
Table 6. Reported procedure- or device-related serious adverse
events during 12-months.
Event %
 In-stent repeat PTA (1 at 3.5 months while 5 between
6±12 months)
4.8
 Embolisation (1 pt ipsilateral SFA during procedure;
1 pt contralateral CIA)
1.6
 Other procedure-related events 1.6
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re-interventions; and 89%, with 4.8% re-interventions,
respectively). Despite the good stenting results
obtained immediately after the intervention and dur-
ing the follow-up period to 12 months in this study, a
substantially large proportion of the patients did not
become or remain symptom-free (34%). In 89% of
these latter patients, however, the stent was found to
be patent, as determined by duplex sonography (PSV
ratio 52.5). Only two of the patients with symptoms
of claudication but in who the PSV ratio was not
determined required intervention at or near the
stented site before 12 months post-stenting. These
data appear to reflect the multi-level progressive ath-
erosclerotic disease afflicting these patients, who were
not pre-selected on the extent of disease, affecting all
vessels and not only the treated vessel segment.
Another interesting finding is that ABI in rest does
not reflect the clinical status of the patient with multi-
level atherosclerotic disease after successful iliac stent
placement, only ABI after exercise shows a significant
decrease of the index.
In conclusion, the results of this multicentre study
with 12-months follow-up again shows stents to be an
effective device in the treatment of iliac artery
obstructive disease. Moreover, this study confirms
the known clinical outcomes and patency rates after
stenting of iliac lesions. The main advantage of a
flexible balloon expandable stent above the Palmaz
stent is enhanced flexibility and modular configur-
ation, thereby rendering it more adjustable to local
morphology. Furthermore, this study also confirms
the concept of iliac stenting on the indication of the
pressure gradient with similar results, concerning
clinical result and haemodynamic patency, to earlier
studies.9 The lost to follow-up at 12 months of 16% of
all included patients could have biased our results
and should be taken into account with this results.
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